Kooi-Heng Ng1, Der-Yuan Chen2, Ching-Heng Lin3, Wen-Cheng Chao4, Yi-Ming Chen5, Yi-Hsing Chen6, Wen-Nan Huang6, Tsu-Yi Hsieh7, Kuo-Lung Lai8, Kuo-Tung Tang1, Hsin-Hua Chen9. 1. Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan. 2. Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan; School of Medicine, China Medical University, Taichung 40447, Taiwan; Translational Medicine Laboratory, Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan. 3. Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung, Taiwan; Department of Healthcare Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan. 4. Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Business Administration, National Changhua University of Education, Changhua, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan. 5. Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Biomedical Science and Rong-Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan. 6. Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan. 7. Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan; Department of Medical Education, Taichung Veterans General Hospital, Taichung, Taiwan; Program of Business, Feng Chia University, Taichung, Taiwan. 8. Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan; Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan. 9. Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan; Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Biomedical Science and Rong-Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan. Electronic address: shc5555@hotmail.com.
Abstract
OBJECTIVE: To assess interstitial lung disease (ILD) risk among patients newly diagnosed with systemic autoimmune rheumatic diseases (SARDs) including rheumatoid arthritis (RA), dermatomyositis (DMtis), polymyositis (PM), systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). METHOD: Using the 1997-2013 Taiwanese National Health Insurance Research Database, we identified 62,930 newly diagnosed SARD patients from 2001 to 2013. We selected 251,720 individuals without SARD diagnoses who were matched (1:4) with SARD patients by age, sex and year of index date. We compared the incidence rates (IRs) of ILD (consistent diagnosis with ICD-9 code 515, 516.3, 516.8, 516.9 or 517 after a ILD-related radiological or pathological procedure) between the specific SARD subgroups and the corresponding non-SARD comparison groups. Using multivariable Cox regression analyses, we estimated hazard ratios (HRs) with 95% confidence intervals (CIs) of ILD in the various SARD groups compared with comparison groups after adjusting for age, sex and Charlson comorbidity index. RESULTS: The IR of ILD was greatest among patients with SSc (1,364 per 105 years), followed by DMtis (1,011 per 105 years), PM (831 per 105 years), pSS (196 per 105 years), RA (109 per 105 years) and SLE (120 per 105 years). Multivariable analyses showed that the risk of ILD was increased among patients with SSc (HR, 172.63), DMtis (HR, 119.61), PM (HR, 84.89), SLE (HR, 32.18), pSS (HR, 17.54), or RA (HR, 8.29). CONCLUSION: This population-based, cohort study demonstrates that the risk of ILD is significantly increased in patients with newly diagnosed SARDs.
OBJECTIVE: To assess interstitial lung disease (ILD) risk among patients newly diagnosed with systemic autoimmune rheumatic diseases (SARDs) including rheumatoid arthritis (RA), dermatomyositis (DMtis), polymyositis (PM), systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). METHOD: Using the 1997-2013 Taiwanese National Health Insurance Research Database, we identified 62,930 newly diagnosed SARDpatients from 2001 to 2013. We selected 251,720 individuals without SARD diagnoses who were matched (1:4) with SARDpatients by age, sex and year of index date. We compared the incidence rates (IRs) of ILD (consistent diagnosis with ICD-9 code 515, 516.3, 516.8, 516.9 or 517 after a ILD-related radiological or pathological procedure) between the specific SARD subgroups and the corresponding non-SARD comparison groups. Using multivariable Cox regression analyses, we estimated hazard ratios (HRs) with 95% confidence intervals (CIs) of ILD in the various SARD groups compared with comparison groups after adjusting for age, sex and Charlson comorbidity index. RESULTS: The IR of ILD was greatest among patients with SSc (1,364 per 105 years), followed by DMtis (1,011 per 105 years), PM (831 per 105 years), pSS (196 per 105 years), RA (109 per 105 years) and SLE (120 per 105 years). Multivariable analyses showed that the risk of ILD was increased among patients with SSc (HR, 172.63), DMtis (HR, 119.61), PM (HR, 84.89), SLE (HR, 32.18), pSS (HR, 17.54), or RA (HR, 8.29). CONCLUSION: This population-based, cohort study demonstrates that the risk of ILD is significantly increased in patients with newly diagnosed SARDs.
Authors: Sara Tomassetti; Thomas V Colby; Athol U Wells; Venerino Poletti; Ulrich Costabel; Marco Matucci-Cerinic Journal: Ther Adv Musculoskelet Dis Date: 2021-12-08 Impact factor: 5.346
Authors: Radjiv Goulabchand; Alain Makinson; Jacques Morel; Philine Witkowski-Durand-Viel; Nicolas Nagot; Paul Loubet; Camille Roubille; Danièle Noel; David Morquin; Kim Henry; Thibault Mura; Philippe Guilpain Journal: Ann Med Date: 2022-12 Impact factor: 5.348